Let's optimize it!

We translate disruptive technologies for accelerated bioprocess development from academia into application. To improve your microbial production. And help you to increase your market success.

 

learn more

Contract research

What we offer

  • Faster innovation cycles through tailor-made solutions to speed up bioprocess development
  • Cutting-edge platforms for detailed and quantitative bioprocess characterization under production-relevant conditions
  • Longstanding expertise in bioprocess analysis and optimization

What we are looking for

  • Challenging tasks in the field of bioprocess characterization, development and optimization.
  • Stakeholders from industrial biotechnology as partners in the open innovation enabling space MiBioLab.
  • Improved research efficiency through bidirectional exchange of knowledge and expertise between MiBioLab and its partners.

 

We are open to new partnerships!

"With Mibiolab we found a trustful partner for our R&D activities with profound expertise in strain characterization and bioprocess optimization."

Alain Sourabié (PhD), Director Science Technology & Innovation Lesaffre - BU Procelys

"We are very pleased about the excellent cooperation with MiBioLab and plan to continue this strategically important partnership on the field of technologies.“

Dr. Christoph Petry, CEO m2p-labs GmbH

"For Enzymaster it is important to work with a reliable partner who has know-how in the field of bioprocess development an optimisation. We found this with MiBioLab."

Dr. Thomas Daußmann, Executive Vice President International Business Enzymaster (Ningbo) Bio-Engineering Co., Ltd., Managing Director Enzymaster Deutschland GmbH

"The improved knowledge about our product application is an asset, supporting us in recommending the optimal Ohly product to our customers to optimize their bioprocesses."

Katelijne Bekers, Business Development Manager Bionutrients Ohly GmbH

"The longstanding expertise in the field of bioprocesses in combination with state of the art technologies have been proven to be a substantial benefit for our research and business."

Dr. Georg Schaumann, CEO SenseUp GmbH